ANG Lifesciences India Limited has announced the appointment of Mrs. Preeti Sarin as an Additional Independent Director to its Board. This appointment, effective from November 14, 2026, will be for a term of five consecutive years, concluding on November 13, 2031, subject to shareholder approval. Mrs. Sarin brings over 10 years of professional experience and possesses strong skills in business administration and management, expected to contribute significantly to the company’s growth and governance.
Board Enhancement at ANG Lifesciences
ANG Lifesciences India Limited has officially announced a key addition to its leadership team with the appointment of Mrs. Preeti Sarin as an Additional Independent Director. This strategic move is intended to further strengthen the company’s board oversight and governance framework.
Appointment Details and Tenure
The appointment of Mrs. Preeti Sarin is effective from November 14, 2026. She will serve in this capacity for a term of five (5) consecutive years. Her tenure is set to conclude on November 13, 2031, inclusive of both dates. This appointment is subject to the necessary approval from the company’s shareholders.
Qualifications and Experience
Mrs. Preeti Sarin is a qualified professional holding a Bachelor of Business Administration (BBA) degree. She possesses over 10 years of extensive professional experience. Her expertise includes a strong understanding of business administration, management, operational coordination, and organizational activities. The company highlighted her strong communication, leadership, and interpersonal skills, as well as her experience in planning and handling administrative responsibilities, which are expected to be invaluable to ANG Lifesciences.
Confirmation of Independence
ANG Lifesciences India Limited confirmed that Mrs. Preeti Sarin meets all the necessary criteria for independence as prescribed under the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. She is not debarred from holding such an office by any order from SEBI or any other relevant authority. Furthermore, it was confirmed that she has no disclosed relationships with any other Director of the Company.
Financial Information
In addition to the board appointment, the company’s Board of Directors also considered and approved the unaudited financial results (standalone and consolidated) for the quarter and half-year ended September 30, 2026. A limited review report by the company’s statutory auditor, M/s Khurana Sharma & Co., was also approved.
Source: BSE
